Andrew Odenwald

Andrew Odenwald is an experienced professional in market access and account management within the pharmaceutical industry. Currently serving as the Director of Market Access Account Management at TG Therapeutics, Inc. since June 2020, Andrew is responsible for managing access strategies and contractual negotiations for specialty products. Previously, Andrew held several roles at Celgene from 2008 to 2020, including Sr. National Account Executive, where the focus was on access strategies and launching multiple products. Earlier roles at Santarus, TAP Pharmaceuticals, and Maxim Healthcare Services further solidified Andrew's expertise in sales management, strategic planning, and reimbursement processes across various healthcare sectors.